<DOC>
	<DOCNO>NCT01653457</DOCNO>
	<brief_summary>Fibromyalgia ( FM ) chronic rheumatic disease high prevalence great clinical impact . However , treatment FM limit efficacy , effect size 0.5 . Recent study find raise level glutamate insula , hippocampus posterior cingulate cortex region brain . This lead number author suggest usefulness glutamate block drug treatment FM . Aims : To evaluate efficacy memantine treatment pain symptoms FM ass efficacy reduce brain glutamate level patient FM . Material method : Randomized controlled trial , six month duration ( include dose adjustment period one month ) . 60 patient FM recruit inclusion study upon fulfillment selection criterion , randomize two group : A ) Treatment group ( n=30 ) , receive 20 mg memantine o.d ; B ) Control group ( n=30 ) receive placebo . The main objective ass efficacy memantine treatment pain ( pain threshold , pain perception ) symptom fibromyalgia ( cognitive state , health status , state anxiety depression , quality life perceive improvement . Discussion : There need development innovative effective alternative treatment FM . This clinical trial determine whether memantine consider option treatment FM patient .</brief_summary>
	<brief_title>Randomised Controlled Trial Memantine Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Male female age 18 65 year . 2 . Ability understand Spanish . 3 . Diagnosis fibromyalgia carry rheumatologist accord American College rheumatology criterion ( ACR1990 ) . 4 . Ability read understand Patient Information Sheet 5 . Signature Informed Consent Form . 6 .In case woman childbearing age , commitment become pregnant entire duration study . 1 . Undergoing drug treatment fibromyalgia . Patients undergoing treatment fibromyalgia stop treatment perform washout period one week . During week patient may take , necessary , analgesic paracetamol , ibuprofen NSAIDS minimize influence medication brain imaging . 2 . Currently take memantine take memantine 2 month prior recruitment . 3 . Another Axis I psychiatric disorder use SCIDI might hinder adherence protocol ( e.g . : dementia , alcohol and/or substance abuse/dependence , schizophrenia , chronic delirium , acute depression ) . 4 . Pregnancy breastfeed . 5 . Hypersensitivity active ingredient , memantine , excipients . 6 . Medical condition require special precaution administer memantine accord summary product characteristic : Epilepsy . Circumstances may cause high urine pH owe Proteus urinary infection , renal tubular acidosis vegetarian diet , recent myocardial infarction , congestive heart disease uncontrolled arterial hypertension . 7 . Clinically significant active evidence liver kidney disease , haematological , respiratory , endocrine cardiovascular disease disorder ( patient control diabetes patient controlled hypertension complete incomplete right bundle branch block include study ) . 8 . Use prescription drug may cause relevant drug interaction memantine accord summary product characteristic : NMDAR antagonist ( amantadine , ketamine , dextromethorphan ) , LDopa , dopamine agonist cholinergic agonist . 9 . Use nonpermitted concomitant medication week prior first evaluation visit patient expect require treatment ( least one drug permit study ) : antidepressant ( duloxetine , venlafaxine , mirtazapine , bupropion , SSRI , etc . ) , analgesic ( pregabalin , gabapentin , opiates , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Fibromyalgia</keyword>
	<keyword>Magnetic Resonance Spectroscopy</keyword>
	<keyword>Memantine</keyword>
	<keyword>electroencephalic cordance</keyword>
</DOC>